Details of the Drug

General Information of Drug (ID: DMDI269)

Drug Name
Docetaxel
Synonyms
EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Breast carcinoma N.A. Approved [1]
Head and neck cancer 2D42 Approved [1]
Leiomyosarcoma 2B58 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Prostate adenocarcinoma N.A. Approved [1]
Prostate cancer 2C82.0 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Urinary system neoplasm N.A. Approved [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01CD02: Docetaxel
L01CD: Taxanes
L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 807.9
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 13
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination
5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 minutes (alpha), 36 minutes (beta), and 11.1 hours (gamma) [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1457 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.1 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0065 mg/mL [3]
Chemical Identifiers
Formula
C43H53NO14
IUPAC Name
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Canonical SMILES
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Cross-matching ID
PubChem CID
148124
ChEBI ID
CHEMBL92
CAS Number
114977-28-5
UNII
699121PHCA
DrugBank ID
DB01248
TTD ID
D0O5WP
VARIDT ID
DR00251
INTEDE ID
DR0520
ACDINA ID
D01011
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [7]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [8]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [16]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Drug Response [17]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [18]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Drug Response [19]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Gene/Protein Processing [20]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Drug Response [21]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Protein Interaction/Cellular Processes [20]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Post-Translational Modifications [20]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Drug Response [22]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [23]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Gene/Protein Processing [24]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Lung tissue
The Studied Disease Lung cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tubulin (TUB) DTT NO-GeName 5.46E-09 0.28 0.72
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Multidrug resistance-associated protein 1 (ABCC1) DTP MRP1 1.90E-30 1.76E-01 7.31E-01
Multidrug resistance-associated protein 7 (ABCC10) DTP MRP7 2.34E-47 4.95E-01 1.54E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 3.87E-47 -1.28E+00 -1.63E+00
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 1.02E-08 -5.12E-02 -2.22E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 3.46E-61 1.83E-01 7.90E-01
TAP-like protein (ABCB9) DTP TAPL 2.04E-01 4.47E-02 1.45E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 2.80E-34 1.44E-01 9.71E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.12E-38 -1.81E+00 -2.01E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Docetaxel
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Docetaxel caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [25]
Armodafinil DMGB035 Minor Increased metabolism of Docetaxel caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
LEE011 DMMX75K Moderate Decreased clearance of Docetaxel due to the transporter inhibition by LEE011. Solid tumour/cancer [2A00-2F9Z] [25]
Coadministration of a Drug Treating the Disease Different from Docetaxel (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Docetaxel caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [25]
Midostaurin DMI6E0R Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [27]
Arn-509 DMT81LZ Moderate Increased metabolism of Docetaxel caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [25]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [28]
Dronedarone DMA8FS5 Major Decreased clearance of Docetaxel due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [25]
Posaconazole DMUL5EW Major Decreased clearance of Docetaxel due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [25]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Docetaxel and Roflumilast. Asthma [CA23] [27]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Docetaxel caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
ABT-492 DMJFD2I Minor Decreased absorption of Docetaxel due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [29]
Troleandomycin DMUZNIG Major Decreased clearance of Docetaxel due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [25]
Erdafitinib DMI782S Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [30]
Lapatinib DM3BH1Y Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [25]
Tucatinib DMBESUA Major Decreased clearance of Docetaxel due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [25]
Palbociclib DMD7L94 Moderate Decreased metabolism of Docetaxel caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Docetaxel caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [25]
Ivacaftor DMZC1HS Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [25]
MK-8228 DMOB58Q Moderate Decreased metabolism of Docetaxel caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [25]
Cenobamate DM8KLU9 Moderate Increased metabolism of Docetaxel caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Stiripentol DMMSDOY Major Decreased metabolism of Docetaxel caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Docetaxel caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Rufinamide DMWE60C Moderate Increased metabolism of Docetaxel caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Docetaxel caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Boceprevir DMBSHMF Major Decreased clearance of Docetaxel due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [25]
Simeprevir DMLUA9D Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [25]
Telaprevir DMMRV29 Major Decreased clearance of Docetaxel due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [25]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Docetaxel and Brentuximab vedotin. Hodgkin lymphoma [2B30] [31]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Docetaxel caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Cobicistat DM6L4H2 Major Decreased clearance of Docetaxel due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [25]
Etravirine DMGV8QU Moderate Increased metabolism of Docetaxel caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Darunavir DMN3GCH Moderate Decreased metabolism of Docetaxel caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Docetaxel and Teriflunomide. Hyper-lipoproteinaemia [5C80] [32]
Tolvaptan DMIWFRL Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [28]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Docetaxel caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [25]
Amobarbital DM0GQ8N Moderate Increased metabolism of Docetaxel caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Docetaxel and Denosumab. Low bone mass disorder [FB83] [33]
Crizotinib DM4F29C Major Decreased clearance of Docetaxel due to the transporter inhibition by Crizotinib. Lung cancer [2C25] [25]
Brigatinib DM7W94S Moderate Increased metabolism of Docetaxel caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [34]
Ceritinib DMB920Z Major Decreased metabolism of Docetaxel caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
PF-06463922 DMKM7EW Moderate Increased metabolism of Docetaxel caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [25]
Osimertinib DMRJLAT Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Osimertinib. Lung cancer [2C25] [25]
Capmatinib DMYCXKL Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [35]
Selpercatinib DMZR15V Moderate Decreased metabolism of Docetaxel caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
Idelalisib DM602WT Major Decreased metabolism of Docetaxel caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
IPI-145 DMWA24P Moderate Decreased metabolism of Docetaxel caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
Vemurafenib DM62UG5 Moderate Increased metabolism of Docetaxel caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
LGX818 DMNQXV8 Moderate Increased metabolism of Docetaxel caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [36]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Docetaxel caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
Danazol DML8KTN Moderate Decreased metabolism of Docetaxel caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [25]
Lasmiditan DMXLVDT Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Lasmiditan. Migraine [8A80] [37]
Exjade DMHPRWG Moderate Decreased metabolism of Docetaxel caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [38]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Docetaxel and Tecfidera. Multiple sclerosis [8A40] [39]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Docetaxel and Siponimod. Multiple sclerosis [8A40] [28]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Docetaxel and Fingolimod. Multiple sclerosis [8A40] [40]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Docetaxel and Ocrelizumab. Multiple sclerosis [8A40] [41]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Docetaxel and Ozanimod. Multiple sclerosis [8A40] [27]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Docetaxel caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [25]
Dasatinib DMJV2EK Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Dasatinib. Myeloproliferative neoplasm [2A20] [25]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Docetaxel and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [42]
Rolapitant DM8XP26 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [43]
Netupitant DMEKAYI Moderate Decreased metabolism of Docetaxel caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [25]
Entrectinib DMMPTLH Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Entrectinib. Non-small cell lung cancer [2C25] [25]
Rucaparib DM9PVX8 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [25]
Abametapir DM2RX0I Moderate Decreased metabolism of Docetaxel caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [44]
Lefamulin DME6G97 Moderate Decreased metabolism of Docetaxel caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [45]
Lonafarnib DMGM2Z6 Major Decreased clearance of Docetaxel due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [25]
Enzalutamide DMGL19D Moderate Increased metabolism of Docetaxel caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [25]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Docetaxel and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [46]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Docetaxel and Canakinumab. Rheumatoid arthritis [FA20] [47]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Docetaxel and Rilonacept. Rheumatoid arthritis [FA20] [47]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Docetaxel and Golimumab. Rheumatoid arthritis [FA20] [48]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Docetaxel when combined with Anthrax vaccine. Sepsis [1G40-1G41] [49]
Voxelotor DMCS6M5 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Voxelotor. Sickle-cell disorder [3A51] [25]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Docetaxel caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [27]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Docetaxel caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [50]
Brilinta DMBR01X Moderate Decreased metabolism of Docetaxel caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [25]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Docetaxel and Valganciclovir. Virus infection [1A24-1D9Z] [28]
⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Docetaxel 20mg/2ml injectable 20mg/2ml Injectable Injection
Docetaxel 80mg/4ml injectable 80mg/4ml Injectable Injection
Docetaxel 160mg/8ml injectable 160mg/8ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Docetaxel FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
7 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
8 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
9 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
12 FDA Drug Development and Drug Interactions
13 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
14 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
15 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
16 Drug Interactions Flockhart Table
17 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
18 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
19 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
20 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
21 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
22 The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem Biol Interact. 2023 Mar 1;373:110372. doi: 10.1016/j.cbi.2023.110372. Epub 2023 Feb 2.
23 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
24 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
25 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
26 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Cerner Multum, Inc. "Australian Product Information.".
29 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
30 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
31 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
32 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
33 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
34 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
35 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
37 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
38 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
39 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
40 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
42 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
43 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
44 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
45 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
46 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
47 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
48 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
49 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
50 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.